Ocumetics Advances Revolutionary Accommodating Intraocular Lens to First-In-Human Surgery This Summer
核心洞察
Ocumetics Technology Corp. (搜索) has completed key milestones for its innovative accommodating intraocular lens (搜索), with first-in-human surgery scheduled for summer 2025 and full results expected by fall.
The Ocumetics Lens (搜索) is designed to fit within the eye's natural lens compartment, utilizing the eye's muscle activity to shift focus naturally from distance to near without requiring glasses or contacts.
Following the initial human trials, the company plans to submit an FDA application in early 2026 for pivotal clinical trials, potentially transforming vision restoration for millions of cataract patients worldwide.
Ocumetics Technology Corp. (搜索) has announced the achievement of several critical milestones that pave the way for First-In-Human (FIH) clinical studies of its innovative accommodating intraocular lens (搜索). The Canadian ophthalmic technology company expects to begin the landmark human surgeries this summer, with initial results available shortly thereafter and comprehensive findings anticipated by fall 2025.
"Advancing a medical device like the Ocumetics Lens (搜索) from concept to First-In-Human evaluation requires a rigorous, structured process to ensure safety, efficacy, and full regulatory compliance," said Dean Burns, President and CEO of Ocumetics. "With the recent completion of numerous critical advancements, we're excited to share our roadmap toward FIH clinical trials."
Breakthrough Technology for Vision Restoration
The Ocumetics Lens (搜索) represents a potentially transformative approach to vision correction. Unlike conventional intraocular lenses used in cataract surgery, this accommodating lens is designed to work with the eye's natural muscular system. By fitting within the natural lens compartment, it allows the eye's muscles to shift focus from distance to near objects, potentially eliminating the need for glasses or contact lenses after cataract surgery.
Dr. Garth Webb, founder and Chief Scientific Officer of Ocumetics, expressed confidence in the technology's potential: "Our team has worked tirelessly to reach this point, and we are confident the FIH study will showcase the transformative potential of our accommodating intraocular lens (搜索). We believe this technology can redefine vision restoration for cataract patients and pave the way to restoring natural, clear vision for millions worldwide."
Final Preparations Underway
The company reports that final preparations for the FIH procedure are well underway, with several critical steps either completed or in progress:
- Laboratory testing has confirmed adequate accommodative power using molded lenses
- Production and quality assurance of design-locked Ocumetics Lenses is ensuring consistency for the study
- Agreements with the clinical study site are being finalized, and a qualified surgeon for the implantation procedures is being selected
- A comprehensive application for regulatory approval is being prepared
- Patient recruitment will identify a diverse, representative study population
Regulatory Pathway and Timeline
Following the FIH surgeries, Ocumetics will conduct extensive post-operative monitoring as part of the regulatory process. The medical team will follow patients for 12 months to evaluate safety and efficacy, with both interim and final results compiled into comprehensive reports for regulatory review.
Burns outlined the company's regulatory timeline: "The FIH surgery and initial study results are expected this summer, with full results anticipated in the fall. We also expect to submit an application to the FDA in early 2026 for pivotal clinical trials, with a target start date in 2026."
Market Impact and Unmet Need
Cataracts (搜索) affect millions of people worldwide and are a leading cause of vision impairment. While standard cataract surgery with conventional intraocular lenses can restore basic vision, patients typically require reading glasses or bifocals for near vision tasks. The Ocumetics Lens (搜索) aims to address this limitation by restoring the eye's natural focusing ability.
If successful in clinical trials, this technology could significantly impact the standard of care for cataract patients. The global market for intraocular lenses is substantial, with millions of cataract surgeries performed annually.
About the Company
Ocumetics Technology Corp. (搜索) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company is currently in the preclinical study stage of what it describes as "game-changing technology for the ophthalmic industry."
The upcoming FIH study represents a critical milestone in the company's development pathway as it works to transform the field of ophthalmology with its innovative approach to vision restoration.